BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:In 2025\, the spotlight is on neurodegenerative drug developme
 nt\, driven by the triumph of Lecanemab and Donanemab\, coupled with rapi
 d advancements to enable presymptomatic diagnosis\, reinvigorating the sp
 ace with new targets\, modalities\, and technologies. Meanwhile significa
 nt advancements to target the likes of α-synuclein\, NLRP3 and GBA sugges
 t only a matter of time until a disease-modifying therapy emerges on the 
 scene for Parkinson's too.\n\nCapitalizing on a new era of revitalized ho
 pe and momentum\, the 13th Alzheimer's and Parkinson's Drug Development S
 ummit returns as the only industry-focused and end-to-end meeting\, with 
 comprehensive coverage spanning early discovery through to late clinical\
 , regulatory\, and commercial development.\n\nJoin industry's premier gat
 hering of 150+ Alzheimer's and Parkinson's experts\, with pioneering insi
 ghts from the likes of Eisai\, Eli Lilly\, Biogen\, and Roche\, as they a
 ddress their most pressing challenges in a collaborative atmosphere to sp
 earhead the next wave of more truly transformative neurodegenerative ther
 apeutics.\n\nURLs:Tickets: https://go.evvnt.com/2732400-2?pid=185Brochure
 : https://go.evvnt.com/2732400-3?pid=185\n\nTime: 8:30 AM - 5:00 PM\n\nSp
 eakers: Alessandro Biffi\, Associate Vice President\, Eli Lilly and Co.\,
  Andre Matta\, Executive Director\, Ventus Therapeutics\, Andrew Kaplan\,
  Principal Scientist\, Bristol Myers Squibb\, Anick Auger\, Head of Pharm
 acology\, Ventus Therapeutics\, Aparna Vasanthakumar\, Senior Principal S
 cientist - Research\, Abbvie\, Beth Hoffman\, Chief Executive Officer\, O
 rigami Therapeutics\, Inc.\, Bruce Morimoto\, Vice President - Drug Devel
 opment\, Alto Neuroscience\, Carrie Rubel\, Scientific Director\, Biomark
 ers\, Biogen\, Chloe Whitehouse\, Senior Specialist\, 3D Technologies\, M
 erck and Co\, Daniel Klamer\, Vice President\, Business Development and S
 cientific Strategy\, Anavex\, Dean Petkanas\, Co-Founder\, Chairman and C
 hief Executive Officer\, KannaLife Sciences Inc\, Edmond Teng\, Senior Gr
 oup Medical Director\, Genentech\, Elena Dale\, Executive Director\, Neur
 oscience\, Bristol Myers Squibb\, Eric Siemers\, Chief Medical Officer\, 
 Acumen Pharmaceuticals\, Fraser Bocell\, Senior Clinical Outcomes Assessm
 ent Scientist\, Critical Path Institute (C-Path)\, Gul Erdemli\, Global P
 rogram Regulatory Director\, Novartis AG\, Ivana Rubino\, Vice President\
 , Head of Global Medical Alzheimer's Disease and MS\, Biogen\, Jackie Oll
 ey-Williams\, Senior Data Scientist\, Eisai\, Janaky Coomaraswamy\, Direc
 tor\, Neuroscience Translational Medicine\, Takeda Pharmaceutical Co. Ltd
 .\, Kaare Bjerregaard-Andersen\, Principal Scientist\, Lundbeck\, Katie P
 laney\, Chief Executive Officer and Board Member\, Acelot\, Inc.\, Kennet
 h Gregory Pugh\, Geriatric Medicine Physician\, Norton Healthcare\, Luis 
 Oliveira\, Senior Associate Director - Research Programs\, The Michael J.
  Fox Foundation for Parkinson's Research\, Malú Tansey\, Director of the 
 Center for Translational Research in Neurodegenerative Disease\, Universi
 ty of Florida\, Manal Morsy\, Chief Regulatory Officer\, Head of Global R
 egulatory Affairs\, Vaxxinity\, Manuela Polydoro\, Vice President\, Head 
 of Translational Medicine\, Muna Therapeutics\, Maria Maccecchini\, Chief
  Executive Officer\, Annovis Bio\, Melody Libby\, Patient Advocacy Lead\,
  Alzheimer's\, Biogen\, Michael Erkkinen\, Instructor in Neurology\, Brig
 ham and Women's Hospital\, Neil Cashman\, Chief Scientific Officer and Co
 -Founder\, ProMIS Neurosciences\, Pallavi Sachdev\, Executive Director\, 
 Translational Medicine\, Eisai\, Paul Edison\, Professor\, Imperial Colle
 ge London\, Peter DiBiaso\, Patient\, The Michael J. Fox Foundation for P
 arkinson's Research\, Ralf Schmid\, Associate Director\, Pre-Clinical Res
 earch\, Novartis AG\, Rebecca Edelmayer\, Vice President\, Scientific Eng
 agement\, Alzheimer's Association\, Sandi See Tai\, Chief Devleopment Off
 icer\, Lexeo Therapeutics\, Sathya Ganesan\, US Regulatory Science Lead\,
  UCB S.A.\, Sean Pintchovski\, Vice President\, Biology\, AcureX Therapeu
 tics\, Shane Hegarty\, Chief Scientific Officer and Co-Founder\, Axonis\,
  Shannon Leslie\, Senior Scientist\, Johnson and Johnson Services\, Inc\,
  Spring Behrouz\, Co-founder and CEO\, Vincere Biosciences\, Steven Arnol
 d\, Managing Director\, Interdisciplinary Brain Center\, Massachusetts Ge
 neral Hopsital\, Tammy Dellovade\, Senior Research Fellow\, Discovery Neu
 roscience\, Abbvie\, Tony Bannon\, Senior Director - Scientific\, Precisi
 on Medicine and Neuroscience\, Abbvie\, Tricia Thornton-Wells\, Senior Di
 rector and Compound Development Team Leader\, Johnson and Johnson Service
 s\, Inc\, Urs Langen\, Lab Head\, Roche\, William Shrader\, Cofounder and
  Chief Scientific Officer\, AcureX Therapeutics\, Xavier Langlois\, Resea
 rch Fellow and Head of Tau Pathobiology\, Abbvie\n
DTEND:20250320T170000
DTSTAMP:20260512T220335Z
DTSTART:20250318T083000
LOCATION:Revere Hotel Boston Common\, 200\, Stuart Street\, Boston\, Massa
 chusetts\, 02116\,
SEQUENCE:0
SUMMARY:In 2025\, the spotlight is on neurodegenerative drug development\,
  driven by the triumph of Lecanemab and Donanemab\, coupled with rapid ad
 vancements...
UID:0967d12f-3f04-45e3-9d96-d14baacbd920
END:VEVENT
END:VCALENDAR